A carregar...
Clinical Benefit Assessment of Vismodegib Therapy in Patients With Advanced Basal Cell Carcinoma
PURPOSE. Vismodegib was approved for the treatment of advanced basal cell carcinoma (aBCC) based on the pivotal ERIVANCE BCC study. The primary endpoint (objective response rate [ORR]) was assessed 9 months after the last patient was enrolled. To confirm the clinical benefit of vismodegib, an additi...
Na minha lista:
| Main Authors: | , , , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AlphaMed Press
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4122481/ https://ncbi.nlm.nih.gov/pubmed/25001266 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2014-0003 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|